X
[{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib in Adults with Heterozygous Familial Hypercholesterolemia and\/or Established Atherosclerotic Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Review Article in ESC\u2019s Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) Inhibition\u2019s Role in Reducing Cardiovascular Disease Risk","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Doses First Patient in PREVAIL, the Cardiovascular Outcomes Trial of Obicetrapib in Adults with Atherosclerotic Cardiovascular Disease (ASCVD)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma to Present at Upcoming Medical Conferences New Post-Hoc Analyses from Phase 2 ROSE Trial of Obicetrapib in Patients with Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Lifesciences Acquisition Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Announces Publication in Nature Medicine Discussing Clinical Potential of Obicetrapib","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$1,061.5 million","upfrontCash":"$121.0 million","newsHeadline":"NewAmsterdam Pharma and The Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$173.5 million","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The net proceeds will be used for the development of TA-8995 (obicetrapib). It is a selective cholesteryl ester transfer protein inhibitor that potently decreases (LDL-C) as well as increases (HDL-C), which is used for the treatment of atherosclerotic Cardiovascular disease.
Lead Product(s):
Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TA-8995
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Jefferies
Deal Size: $173.5 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
February 13, 2024
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor having the potential for lowering LDL-C. It is currently being investigated in combination with ezetimibe as an adjunct to high-intensity statin therapy.
Lead Product(s):
Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TA-8995
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 05, 2023
Details:
Proceeds from this transaction will be used for three ongoing phase 3 trials, BROADWAY, BROOKLYN and PREVAIL, evaluating the effect of TA-8995 (obicetrapib) in patients with atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia.
Lead Product(s):
Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TA-8995
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Frazier Healthcare Partners
Deal Size: $235.0 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
November 23, 2022
Details:
Treatment with TA-8995 (obicetrapib) in patients on high-intensity statin therapy was observed to have statistically significant impact on LDL-C, as well as significant impacts on ApoB, non-HDL-C, HDL-C and Lp(a), additional key measures of cardiovascular disease risk.
Lead Product(s):
Obicetrapib ,Atorvastatin
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TA-8995
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Frazier Healthcare Partners
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 11, 2022
Details:
NewAmsterdam is investigating TA-8995 (obicetrapib), a next-generation oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C-lowering therapy for high-risk cardiovascular disease (“CVD”) patients.
Lead Product(s):
Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TA-8995
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Frazier Lifesciences Acquisition Corporation
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Merger
July 25, 2022
Details:
NewAmsterdam is investigating TA-8995 (obicetrapib), a next-generation oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C-lowering therapy for high-risk cardiovascular disease (“CVD”) patients.
Lead Product(s):
Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TA-8995
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Frazier Healthcare Partners
Deal Size: $235.0 million
Upfront Cash: Undisclosed
Deal Type: Financing
July 25, 2022
Details:
Under the collaboration agreement, NewAmsterdam will retain all rights to commercialize obicetrapib in cardiovascular diseases, if approved, in the rest of the world, as well as rights to develop certain forms of TA-8995 for other diseases such as Alzheimer's disease.
Lead Product(s):
Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TA-8995
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Menarini
Deal Size: $1,061.5 million
Upfront Cash: $121.0 million
Deal Type: Licensing Agreement
June 28, 2022
Details:
TA-8995 (Obicetrapib) is a next-generation oral, low-dose and once-daily CETP inhibitor in development for lowering low-density lipoprotein cholesterol (LDL-c) and preventing major adverse cardiovascular events.
Lead Product(s):
Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TA-8995
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 06, 2022
Details:
TA-8995 (obicetrapib) is next-generation CETP inhibitor, initially in development for patients at high risk for cardiovascular disease as an adjunct to maximally tolerated statin therapy, both as a monotherapy and in a fixed-dose combination with ezetimibe.
Lead Product(s):
Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TA-8995
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 19, 2022
Details:
PREVAIL evaluates whether obicetrapib, a novel cholesteryl ester transfer protein inhibitor, lowers the risk of adverse cardiovascular outcomes in individuals with ASCVD, who are not adequately controlled despite maximally tolerated lipid-modifying therapies.
Lead Product(s):
Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: TA-8995
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 01, 2022